RANDOX LABORATORIES, LTD.
|RANDOX LABORATORIES, LTD. Patent applications|
|Patent application number||Title||Published|
|20130121878||REAGENT BOTTLES, VALVES THEREFOR, WASHING MODULES AND METHODS AND APPARATUS FOR DISPENSING REAGENTS - A valve for a reagent bottle is provided, the valve including a resilient membrane configured to extend across an opening in the reagent bottle, the resilient membrane having at least one slit extending therethrough. Also disclosed is a dispensing apparatus for dispensing a reagent from a reagent bottle, the dispensing apparatus comprising: a probe assembly having a probe adapted for insertion into the reagent bottle through the valve and an extraction mechanism for drawing reagent out of the reagent bottle through the probe. A valve opening assembly is provided, which is adapted to open the valve of the reagent bottle such that the probe can pass through the valve without contacting the valve.||05-16-2013|
|20120208294||IMMUNODETECTION AND QUANTIFICATION OF PYRAZOLOPYRIMIDINE SEDATIVES - The invention relates to novel immunogens, antibodies, methods and kits for use in immunoassays to detect and quantify zaleplon, metabolites of zaleplon and indiplon. These are the first described immunoassays for these compounds and have greater sensitivity than alternative analytical techniques.||08-16-2012|
|20120142548||METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF ALZHEIMER'S DISEASE - The invention relates to methods of diagnosing Alzheimer's disease (AD) in a subject and methods of determining the prognosis in patients with AD. The adhesion molecules P-selectin and L-selectin are described for the first time for use as biomarkers to aid in the diagnosis of AD. The invention further describes the use of one or more of L-selectin, MCP-1, IL-1α, IL-8 and IFN-γ to aid in the prognosis of either accelerated cognitive decline (ACD) or slow cognitive decline (SCD) in patients with AD.||06-07-2012|
|20120135434||MCPP IMMUNOASSAY - The invention describes a practical and robust multi-antibody approach to the sensitive immunodetection and determination of the drug of abuse m-chlorophenyl piperazine (mCPP). The invention also describes methods and kits for mCPP detection in an in vitro sample.||05-31-2012|
|20100291600||Immunoassay - The present invention provides an immunoassay method for detecting or determining the amount of salvinorin A, salvinorin B and/or analogues thereof in an in vitro sample, an antibody for salvinorin A, salvinorin B and/or analogues thereof and a kit for detecting the presence of or determining the amount of salvinorin A, salvinorin B and its analogues thereof in a sample.||11-18-2010|
|20100047770||Detection of Breast Cancer - A method for the detection of the presence or risk of cancer in a patient, comprises the steps of: (i) isolating a sample of the patient's genome; and (ii) detecting the presence or expression of the gene characterized by any of the nucleotide sequences identified as SEQ ID No 1, SEQ ID No. 10 and SEQ ID No. 13 wherein the presence or expression of the gene indicates the presence of or the risk of cancer.||02-25-2010|
|20090311671||Diagnosis of risk of breast cancer - A diagnostic method is disclosed which can he used to predict the risk of cancer, in particular breast cancer. The method comprises: (i) isolating a sample of the patient's genome: and (ii) detecting the presence or expression of the gene comprised within the sequence identified herein as SEQ ID No. 1, wherein the presence or expression of the gene indicates the presence of or the risk of cancer.||12-17-2009|
|20090192107||Breast Cancer Markers - A method for the detection of the presence of or the risk of cancer in a patient, comprising, with reference to a normal control, the step of: (i) detecting the expression level of a gene characterised by any of the nucleotide sequences identified herein as SEQ ID No. 1 to SEQ ID No. 10, in a sample isolated from a patient, wherein an increased expression level of the gene characterised by any of SEQ ID Nos. 1 to 6 and 10, or a decreased expression level of the gene characterised by any of SEQ ID Nos. 7 to 9, indicates the presence of or the risk of cancer in the patient from whom the sample was isolated.||07-30-2009|
|20090053824||Assay Device Processing Apparatus and Method - Assay device processing apparatus includes a rotatably mounted assay device vessel support; and a drive for rotating the support. The support is rotatable about a substantially horizontal first axis so that, upon rotation, an assay device vessel attached to the support can be inverted.||02-26-2009|
|20080318229||Method for Diagnosing Neuro-Degenerative Disease - A method for the diagnosis of Alzheimer's Disease (AD) or Parkinson's Disease (PD), comprises measuring the level of expression of one or more AD markers (Table 1) or PD markers (Table 2) in a sample of platelets isolated from a person suspected of having AD or PD, and determining whether the levels of expression are altered compared to a control.||12-25-2008|
|20080206780||Antibody Libraries - The invention relates to a composition comprising a plurality of antibody fragments, each comprising a framework region having a murine VH14 heavy chain and a murine VK2 light chain, or homologues thereof, each antibody fragment further comprising at least one different CDR.||08-28-2008|
Patent applications by RANDOX LABORATORIES, LTD.